China is aiming to vaccinate 70-80 percent of its population by the end of this year or mid-2022, the head of the country’s Center for Disease Control said Saturday.
With four approved vaccines, China will vaccinate 900 million to 1 billion people, Gao Fu, the CDC head, said in an interview with Chinese state media broadcaster CGTN. “We hope that China can take the lead in achieving herd immunity in the world,” he said.
Herd immunity occurs when enough of the population has immunity, either from vaccination or past infection, to stop the uncontrolled spread of an infectious disease like COVID-19.
China had administered 52.5 million vaccine doses through the end of February. It has been slower in its vaccination campaign than many other countries, including the US, government health experts have acknowledged. China has committed roughly 10 times more doses abroad than it has distributed at home.
Although emergency vaccinations have been underway in China since at least last summer, the country has been slow to announce whether it had any plans to achieve herd immunity.
China has approved four domestically made vaccines: two from state-owned Sinopharm, one from Sinovac, and another from CanSino. None of the four vaccines have publicly released their final stage trial data.
China currently has 17 COVID-19 vaccine candidates for clinical trials.
UAE vaccinates 48 percent of population, plans to open seven field hospitalsThe United Arab Emirates is moving closer towards its March target of 50 percent vaccination coverage, with 48 percent of its population now having ... Coronavirus
UAE may ‘soon’ be first country to vaccinate all population, reach herd immunity: DocThe United Arab Emirates is on track to be among the first nations to emerge from the COVID-19 pandemic by vaccinating most of its population in an ... Coronavirus
UAE prioritized early availability, local production in picking Sinopharm vaccineThe United Arab Emirates hinged its inoculation program on the vaccine developed by China’s Sinopharm Group, given early availability and the ... Coronavirus